Literature DB >> 20972557

Earlier discovery of pregabalin's dependence potential might have been possible.

Ola Caster, I Ralph Edwards, G Niklas Norén, Marie Lindquist.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20972557     DOI： 10.1007/s00228-010-0920-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  2 in total

1.  Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2005-07-28

2.  A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system.

Authors:  Sofie Schwan; Anders Sundström; Elisabet Stjernberg; Ebba Hallberg; Pär Hallberg
Journal:  Eur J Clin Pharmacol       Date:  2010-06-19       Impact factor: 2.953
  2 in total
  14 in total

Review 1.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Correspondence (letter to the editor): One-sided publication.

Authors:  Günther Egidi
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

3.  Detection of signals of abuse and dependence applying disproportionality analysis.

Authors:  V Pauly; M Lapeyre-Mestre; D Braunstein; M Rueter; X Thirion; E Jouanjus; J Micallef
Journal:  Eur J Clin Pharmacol       Date:  2014-11-20       Impact factor: 2.953

4.  Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.

Authors:  Damien Driot; Emilie Jouanjus; Stéphane Oustric; Julie Dupouy; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2019-03-28       Impact factor: 4.335

5.  Pregabalin abuse and dependence in Germany: results from a database query.

Authors:  Maximilian Gahr; Roland W Freudenmann; Christoph Hiemke; Makus A Kölle; Carlos Schönfeldt-Lecuona
Journal:  Eur J Clin Pharmacol       Date:  2013-01-05       Impact factor: 2.953

6.  Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications.

Authors:  Arton Baftiu; Cecilie Johannessen Landmark; Ida Rudberg Rusten; Silje Andrea Feet; Svein I Johannessen; Pål G Larsson
Journal:  Eur J Clin Pharmacol       Date:  2016-07-13       Impact factor: 2.953

7.  Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.

Authors:  Jean-Baptiste Bossard; Camille Ponté; Julie Dupouy; Maryse Lapeyre-Mestre; Emilie Jouanjus
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

8.  Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database.

Authors:  Régis Fuzier; Isabelle Serres; Emmanuelle Guitton; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2013-01       Impact factor: 5.606

9.  Pregabalin abuse among opiate addicted patients.

Authors:  Martin Grosshans; Tagrid Lemenager; Christian Vollmert; Nina Kaemmerer; Rupert Schreiner; Jochen Mutschler; Xenija Wagner; Falk Kiefer; Derik Hermann
Journal:  Eur J Clin Pharmacol       Date:  2013-08-30       Impact factor: 2.953

10.  A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

Authors:  Stefania Chiappini; Fabrizio Schifano
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.